<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-139287</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Acute kidney failure secondary to a combination of renin-angiotens in system inhibitors, diuretics and NSAIDS. The 'Triple Whammy'</dc:title>
<dc:description xml:lang="en">Introduction: Renin-angiotens in system inhibitors (ACEIs/ARBs), diuretics and non-steroidalanti-inflammatory drugs (NSAIDs) &#151; a combination also known as the Triple Whammy(TW) - can reduce the glomerular filtration rate (GFR) and lead to acute kidney injury (AKI). Objective: To study the incidence of AKI due to any type or combination of drugs. To describe patient profiles admitted for outpatient AKI due to TW drugs (AKI-TW), hospital costs and mortality. Methods: This was a 15-month retrospective observational study, developed in 3 stages:- First stage: Cross-sectional description of outpatient AKI-TW hospitalisation episodes.- Second stage: Outpatient drug consumer cohort follow-up (15,307 individuals).- Third stage: Mortality and costs evaluation. It included 62 patients with AKI-TW and62 without, paired by medical specialty, gender, age and comorbidity according to the Clinical Risk Groups (CRG) system. Results: There were 85 hospitalisation episodes attributed to AKI-TW; 78% of cases were older than 70 years. Incidence of AKI-TW was 3.40 cases/1000 users/year (95% CI: 2.59-4.45). Double therapy with NSAIDs + diuretics was 8.99 (95%CI 3.16-25.3); Triple Whammy was8.82 (95% CI 4.4-17.3); double therapy with ACEIs/ARBs + diuretics 6.87 (95% CI 4.81-9.82); and diuretics in monotherapy 3.31(95% CI 1.39-7.85). Mean stay for cases was 7.6 days (SD6.4) and total avoidable costs were &#128;214,604/100,000 inhabitants/year. Mortality during hospital stay and at 12 months was 11.3% and 40.3% respectively, without significant differences between groups. Conclusions: Triple Whammy therapy is associated with a high incidence of hospital admission for AKI. Diuretics in monotherapy, double and combined triple therapy are associated with a high incidence of AKI. AKI-TW involves high hospital costs andavoidable mortality (AU)</dc:description>
<dc:creator>Cols, Montse</dc:creator>
<dc:creator>Coderch, Jordi</dc:creator>
<dc:creator>Garcia Camin, Rosa Maria</dc:creator>
<dc:creator>Leonel Chevarria, Julio</dc:creator>
<dc:creator>García Osuna, Rosa</dc:creator>
<dc:creator>Lisbona, Josep Maria</dc:creator>
<dc:creator>Carreras, Mar</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Inhibidores del sistema renina-angiotensina (IECAS/ARA II), diuréticos y AINES, combinación conocida como 'Triple Whammy', pueden producir descenso de filtradoglomerular y fracaso renal agudo (FRA). Objetivos: Describir la incidencia de FRA para cada tipo de fármaco y sus combinaciones. Caracterizar el perfil de paciente que ingresa por FRA extrahospitalario secundario a fármacos de la Triple Whammy (FRAETW), evaluando costes y mortalidad. Métodos: estudio observacional retrospectivo realizado durante 15 meses y desarrollado en tres etapas:- 1º Etapa transversal de identificación y descripción de los ingresos hospitalarios por FRAETW.- 2º Etapa de seguimiento de una cohorte ambulatoria consumidora de estos fármacos (15.307 consumidores)- 3º Etapa de cohortes para evaluar costes y mortalidad, contrastando 62 pacientes ingresados con FRAETW, con 62 pacientes sin FRA, apareados por especialidad médica, sexo, edad y comorbilidad según Clinical Risk Groups. Resultados: 85 ingresos por FRAETW, 78% mayores de 70 años. Incidencia poblacional de FRAETW: 3,40 casos/1.000 consumidores/año (IC95% 2,59-4,45). Por categorías: AINES +diuréticos 8,99(IC95% 3,16-25,3), la 'Triple Whammy' 8,82(IC 95% 4,4-17,3), IECA/ARA II+ diuréticos 6,87 (IC95% 4,81-9,82) y la monoterapia con diuréticos 3,31(IC95% 1,39-7,85). Estancia media 7,6 días (DE 6,4), estimándose coste medio evitable de 214.604 &#128;/100.000habitantes/año. Mortalidad del 11,3% durante el ingreso y del 38,7% a los 12 meses, sin diferencias significativas con los controles. Conclusiones: El tratamiento con IECA, ARA II, diuréticos y/o AINES presenta elevada incidencia de ingreso por FRA, siendo los diuréticos en monoterapia, doble y triple terapia combinada los que ocasionan la mayor incidencia. El FRAETW supone elevados costes sanitarios y muertes evitables (AU)</dc:description>
<dc:source>Nefrologia;35(2): 197-206, mar.-abr. 2015. ilus, tab</dc:source>
<dc:identifier>ibc-139287</dc:identifier>
<dc:title xml:lang="es">Fracaso renal agudo secundario a combinación de inhibidores del sistema renina-angiotensina, diuréticos y AINES. 'La Triple Whammy'</dc:title>
<dc:subject>^d22832^s22020</dc:subject>
<dc:subject>^d4419^s22020</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d27938^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d4294^s22020</dc:subject>
<dc:subject>^d53982^s22036</dc:subject>
<dc:subject>^d4409</dc:subject>
<dc:type>article</dc:type>
<dc:date>201504</dc:date>
</metadata>
</record>
</ibecs-document>
